A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)

Inclusion Criteria: Patients eligible for inclusion in this study have to meet all of the following criteria: * Patients, 18 years of age or older * Competent and able to comprehend, sign and date an Ethics Committee (EC) approved Informed Consent Form (ICF) before performance of any study-specific procedures or tests * Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures * Histologically proven diagnosis solid tumor * Diagnosis of advanced or locally advanced disease * Patients candidated to receive standard therapy in the following line: * first, second or third-line therapy for colon-rectal cancer in IV stage * first or second-line therapy for gastric cancer in IV stage * primary intent or first-line therapy for pancreatic cancer * first-line therapy for bile duct cancer * first or second-line therapy for hepatocarcinoma * first, second, third, fourth or fifth-line therapy for breast cancer in IV stage * chemotherapy for ovarian cancer in advanced stage (FIGO III-IV) and at the time of first relapse * first or second-line therapy for endometrial cancer in advanced stage (FIGO III-IV) * first or second-line therapy for advanced or locally advanced cervical cancer * therapy for locally advanced or first line therapy for metastatic vulva cancer * first, second or third-line therapy for melanoma (third-line therapy only in BRAF-mutated melanoma) Exclusion Criteria: * Diagnosis of any secondary malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix. * Patients unable or unwilling to undergo as per protocol assessments at the four planned timepoints